PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 19, 2026Cancer Research0 citations

Abstract LB310: Adipose-targeted electrical stimulation suppresses metastasis in obesity-associated TNBC

View Full Paper
SYSohae YangDaegu Gyeongbuk Institute of Science and TechnologyHKHyun Gyu KangDaegu Gyeongbuk Institute of Science and TechnologyMKMinseok S. KimBrigham and Women's Hospital

Key Points

  • This research aims to examine the effect of electrical stimulation on preventing metastasis in triple-negative breast cancer associated with obesity.
  • Developed an in vitro 3D adipocyte-TNBC coculture and screening platform (HiTESOC).
  • Applied electrical stimulation to adipose tissue in a diet-induced obese TNBC mouse model every other day for 4 weeks.
  • Measured metastatic burden through lung weight and bioluminescence signal, as well as circulating adipokines and inflammatory markers.
  • Electrical stimulation significantly reduced metastatic burden in the lungs of obese mice.
  • Stimulated adipose tissue was preserved, and tumor-induced adipocyte remodeling was partially reversed.
  • Circulating TNFα levels decreased, adiponectin levels modestly increased, and plasma free fatty acids lowered, suggesting reduced inflammation.

Abstract

Abstract Obesity makes triple-negative breast cancer (TNBC) more lethal by amplifying adipocyte-tumor crosstalk, with excess lipids and chronic inflammatory cytokines as key drivers of metastasis. However, no effective, well-tolerated therapy directly targets this axis in obesity-associated TNBC. Systemic anti-obesity pharmacotherapy may be limited by tolerability and unclear interactions with cancer therapy. Therapies that directly and locally disrupt this adipose-driven axis remain limited. This unmet need motivates a local, nonpharmacologic electroceutical approach—electrical stimulation (ES) —directed at adipose tissue remodeled by obesity and tumor signaling. ES is designed to disrupt metastasis-promoting adipocyte-tumor crosstalk while minimizing systemic exposure, primarily by modulating adipokine secretion, lipid metabolism, and adipocyte remodeling. We hypothesized that adipose-targeted ES could reverse pro-metastatic adipose remodeling, reshape a metastasis-permissive microenvironment, and ultimately limit metastatic dissemination in obesity-associated TNBC. To identify effective ES conditions, we developed an in vitro 3D adipocyte-TNBC coculture and ES screening platform (HiTESOC) that delivers adipocyte-specific, spatially uniform stimulation across defined pulse conditions. We quantified free fatty acid (FFA) release, adipokine profiles, and EMT-related gene expression in tumor cells to identify anti-metastatic ES parameters. The top regimen was then applied in an orthotopic, diet-induced obese TNBC BALB/c model by implanting tumor cells into the mammary fat pad and stimulating the contralateral pad with a surface electrode on the abdominal skin every other day for 4 weeks. ES significantly reduced metastatic burden in obese mice without altering primary tumor weight, as shown by lower lung weight and decreased lung bioluminescence signal. ES preserved the stimulated fat pad and partially reversed tumor- and obesity-induced adipocyte remodeling. Systemically, ES decreased circulating TNFα, modestly increased adiponectin, and lowered plasma FFAs, indicating dampened inflammatory tone and reduced lipid fuel availability. Within tumors, ES increased tumor-infiltrating lymphocytes, consistent with conversion to a less metastasis-permissive immune microenvironment. In obesity-associated TNBC, where systemic metabolic inflammation fuels metastasis, our data show that localized adipose electroceutical stimulation can decouple adipose dysfunction from metastatic spread—providing a practical, drug-sparing strategy to limit dissemination while avoiding systemic toxicity. Citation Format: Sohae Yang, Hyun Gyu Kang, Minseok S. Kim. Adipose-targeted electrical stimulation suppresses metastasis in obesity-associated TNBC abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts) ; 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86 (8Suppl): Abstract nr LB310.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Yang et al. (2026) studied this question.

synapsesocial.com/papers/69e47376010ef96374d8f4a0https://doi.org/10.1158/1538-7445.am2026-lb310
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract PO1-06-13: Plasma Exosomes in Obesity-driven Diabetes Exacerbate Progression of Triple Negative Breast Cancer: Insights from Animal Models2024 · 2 citations
  2. 2Abstract 3637: Improving therapeutic efficacy by targeting adenosine signaling in obese breast cancers2026
  3. 3Abstract PS3-12-13: Adipocyte-tumor cell interactions drive aggressiveness in triple-negative breast cancer2026
  4. 4Abstract PS3-04-22: A mathematical framework to optimize combination therapy for triple-negative breast cancer in obese mice2026
  5. 5Abstract 7793: Bioelectromagnetic reprogramming of tumor-immune metabolism to selectively destroy NSCLC2026